Clinical trials of agents that reverse multidrug resistance. A literature review

Cancer

Volumn 72, Issue 12, 1993, Pages 3553-3563

  Raderer, Markus ^a   Scheithauer, Werner ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

clinical trials; multidrug resistance; P glycoprotein; resistance modifiers

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; PREDNISONE; QUINIDINE SULFATE; TAMOXIFEN; TOREMIFENE; TRIFLUOPERAZINE; VERAPAMIL; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

CLINICAL TRIALS; CYCLOSPORINS; DRUG RESISTANCE; HUMAN; P-GLYCOPROTEIN; PHENOTYPE; QUINIDINE; TAMOXIFEN; TRIFLUOPERAZINE; VERAPAMIL;

EID: 0027136660     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19931215)72:12<3553::AID-CNCR2820721203>3.0.CO;2-B     Document Type: Review

References (71)

1. The biochemistry of P‐glycoprotein‐mediated multidrug resistance
2. The potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomyan
3. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
4. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug‐resistant tumour cells
5. Increased accumulation of vincristine and adriamycin in drug‐resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors
6. Reversal of acquired resistance to doxorubicin in P388 murine cell leukemia cells by tamoxifen and other triparanol analogues
7. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance
8. Targeting chemosensitizing doses of toremifene based on protein binding
9. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multidrug resistant human lung cancer cell line
10. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells
11. Reversal of multidrug resistance
12. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P‐glycoprotein on specific sites, and transport of verapamil outward across the plasma membrane of K 562/ADM cells
13. Modulators of P‐glycoprotein associated multidrug resistance
14. Verapamil restoration of daunorubicin responsiveness in daunorubicin resistant Ehrlich ascites carcinoma
15. Potentiation of etoposide induced DNA‐damage by calcium antagonists in L1210 cells in vitro
16. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate
17. Enhancement of cytogenetic and cytotoxic effects on multidrug‐resistant (MDR) cells by a calcium antagonist (verapamil)
18. Verapamil plus adriamycin: a Phase I‐II clinical study [abstract]
19. Verapamil and adriamycin in the treatment of drug resistant ovarian cancer patients
20. Clinical trial of continuous infusion verapamil, bolus vinblastine and continuous infusion VP‐16 in drug resistant pediatric tumors
21. Drug resistance in multiple myeloma and non‐Hodgkin's lymphoma: detection of P‐glycoprotein and potential circumvention by addition of verapamil to chemotherapy
22. Clinical modulation of doxorubicin resistance by the calmodulin inhibitor trifluoperazine: a Phase I/II trial
23. Chemotherapy (vinblastine) and inhibitor (quinidine sulfate) multidrug resistance in the treatment of metastatic renal carcinoma [abstract]
24. Intermittent high dose tamoxifen (HDT) with oral etoposide (EPO): Phase I and II clinical studies
25. In vitro and in vivo studies on the effect of cyclosporin A in the circumvention of multidrug resistance
26. Enhancement of vincristine‐ and adriamycin‐induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin
27. Multidrug resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer
28. P‐glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high‐dose verapamil
29. Reversal of multidrug resistance
30. 4′epidoxorubicin plus verapamil in anthracycline‐refractory cancer patients
31. A Phase II study of intensive‐dose epirubicin/verapamil as induction therapy followed by intensive‐dose ifosfamide for advanced breast cancer
32. Can verapamil induce second response to patients refractory to vincristine?
33. Lack of reversal with verapamil of drug resistance in multiple myeloma
34. Verapamil with mitoxantrone for advanced ovarian cancer: a negative Phase II trial
35. The effect of dextro‐, levo‐, and racemic verapamil on atrioventricular conduction in humans
36. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific
37. Phase I and pharmacokinetik study of D‐verapamil and doxorubicin
38. Drug resistance in malignant lymphoma: experience with EPOCH chemotherapy [abstract]
39. Zytostatische Chemotherapie mit Adriamycin und R‐Verapamil als Modulator der Multidrug‐Resistenz: Eine Phase I/II Studie bei Patientinnen mit metastasiertem Mammakarzinom [abstract]
40. A Phase II study of d‐verapamil (dvpm) plus doxorubicin in advanced colorectal cancer [abstract]
41. Phase I/II study of d‐verapamil (dvpm), epirubicin and GmCSF in advanced pancreatic cancer [abstract]
42. P‐glycoprotein expression in primary breast cancer detected by immunochemistry with two monoclonal antibodies
43. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer
44. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo
45. Drugs and the treatment of psychiatric disorders
46. Correlation between potency of calmodulin inhibitors and effect on cellular levels and cytotoxic activity of doxorubicin (adriamycin) in resistant P388 mouse leukemia cells
47. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention and cytotoxicity of anthracyclines in doxorubicin (adriamycin)‐resistant P388 mouse leukemia cells
48. Phase I trial of high dose tamoxifen and 5 day infusion of vinblastine as an approach to reverse multidrug resistance [abstract]
49. Pharmacokinetic study of high dose tamoxifen with daunorubicin: a Phase I trial with escalation of tamoxifen [abstract]
50. Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer: a Phase I/II study
51. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug resistance gene
52. Phase II study of combining vinblastine and cyclosporin A to circumvent multidrug resistance in renal cell cancer
53. Biochemical modulation of anthracycline resistance (MDR) in acute leukemia with cyclosporin A (CSA) [abstract]
54. Multidrug resistance in hematopoetic tumors [abstract]
55. Feasibility of using quinine, a potential multidrug resistance‐reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leucemia
56. Modulation of multidrug resistant multiple myeloma by cyclosporin: The Leukemia Group of the EORTC and the HOVON
57. Expression of the MDR‐1/p‐glycoprotein in human colon cancer cell lines
58. Various methods of analysis of MDR‐1/p‐glycoprotein in human colon cancer cell lines
59. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance
60. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen‐induceg resistance to xenobiotics in rats
61. Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant humen breast cancer cell
62. Resistance modification by PCS‐833, a novel non‐immunosuppressive cyclosporin A
63. SDZ 280‐446, a novel semisynthetic cyclopeptolide: in vitro and in vivo circumvention of the P‐glycoproteinmediated tumour cell multidrug resistance
64. Quinidine (Q) and the tiapamil analogue Ro11‐2933 (Ro) modulate multidrug resistance (MDR) in a human tumour xenograft model
65. Characterization of the reversal of multidrug resistance by S 9788, a new triazinoaminopiperidine derivative
66. Enhancement of drug efficacy by the new calcium channel blocker B8509‐035 in the BRO/mdr1.1 model
67. Combined chemosenitization for reversing MDR1: synergism of verapamil with quinine but antagonism with quinidine
68. Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines
69. Transgenic mice that express the human multidrug‐resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance
70. In vivo concentration of serum proteins significantly inhibits reversal of P‐glycoprotein‐mediated drug resistance by some chemosensitizers
71. Identification of potentially useful chemosensitizers to reverse multidrug resistance